Delaware court refuses to enforce Fresenius/Akorn merger agreement
A judge has ruled that healthcare company Fresenius was entitled to pull out of a planned $4.75 billion takeover of generic drugmaker Akorn, after finding that the target made false representations about the state of its data.
To read more
Subscribe to Global Data Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Data Review experts.